哮喘急性期治疗前、后血清3项指标浓度变化的研究  

Study on the changes of cytokine in the acute exacerbations of asthma patients before and after treatment

作　　者：李莉[1] 余丽清[1] 李莉佳[1] 

机构地区：[1]四川省攀枝花市中西医结合医院检验科,617000

出　　处：《检验医学与临床》2009年第13期1046-1047,共2页Laboratory Medicine and Clinic

摘　　要：目的观察哮喘急性期患者治疗前、后血清白细胞介素-4(IL-4)、IL-16、内皮素-1(ET-1)浓度的变化,研究其与疾病进展的关系。方法使用酶联免疫吸附试验(ELISA)检测51例哮喘急性期患者治疗前、后血清IL-4、IL-16、ET-1的浓度变化。另设健康对照组30例。结果(1)哮喘急性期和缓解期IL-4、IL-16、ET-1均显著高于对照组,差异有统计学意义(P<0.05);(2)缓解期IL-4、ET-1较治疗前明显降低,差异有统计学意义(P<0.05),IL-16较治疗前下降不明显,差异无统计学意义(P>0.05)。结论IL-4、IL-16、ET-1参与支气管哮喘发病的整个过程,其检测有助于病情评估与治疗。同时提示,哮喘急性期缓解后气道炎性反应仍持续存在。Objective To observe the changes of interleukin-4（IL-4）and 16（IL-16） ,and Endothelin-l（ET-1） in the acute exacerbations of asthma patients before and after treatment. Methods The serum levels of IL-4,IL-16 and ET-1 were measured by ELISA method in 51 cases of acute exacerbations of asthma before and after treatment. Results The levels of IL-4,IL-16 and ET-1 of the patients with asthma at both acute attack and convalescence stages were significantly higher than that of those in healthy controls. The levels of IL-4 and ET-1 in convalescence stages were significantly decreased as the one during acute attack stages, and the levels of IL-16 in convalescence stages were not sig.nificantly decreased as the one in acute attack stages. Conclusion IL-4,IL-16 and ET-1 may be involved in the pathogenesis of asthma. There is some clinical value to determine the dynamic changes of IL-4, IL-16 and ET-1 levels in patients with bronchial asthma. The immunologic imbalance exists in patients with bronchial asthma at both acute attack and convalescence stages.

关 键 词：支气管哮喘 白细胞介素 内皮素 

分 类 号：R562.25[医药卫生—呼吸系统] R47[医药卫生—内科学]